Go back to News
NEWS
GA_P advises Uriach on the minority investment in ICG and the acquisition of French group Laboratories Ineldea
15 November, 2023
AGómez-Acebo & Pombo has advised Grupo J. Uriach, a Catalan company specialising in the Natural Consumer Healthcare sector, on the entry of the private equity fund ICG in its share capital and on the simultaneous acquisition of the French group Laboratories Ineldea.
With this acquisition, Grupo J. Uriach aims to have a turnover of 450 million euros by 2025, in addition to consolidating its leadership in the Natural Consumer Healthcare business in Europe and strengthening its position in the countries where it already operates, consolidating more powerful local businesses.
The closing of both transactions is subject, among others, to regulatory approvals.
The GA_P team has been led by Daniel Marín, Carolina Posse and Beatriz Dosdá, partner and associates of Corporate, together with Zina Safer, head of the legal department of Grupo J. Uriach. Uriach Group. The transaction has also been advised by Iñigo Igartua, Andrea Díez de Uré and Jesús Urriza, partner and associates of Competition, and Rafael Aguilera and Iñigo Arrieta, partner and associates of Banking.
Read full article
With this acquisition, Grupo J. Uriach aims to have a turnover of 450 million euros by 2025, in addition to consolidating its leadership in the Natural Consumer Healthcare business in Europe and strengthening its position in the countries where it already operates, consolidating more powerful local businesses.
The closing of both transactions is subject, among others, to regulatory approvals.
The GA_P team has been led by Daniel Marín, Carolina Posse and Beatriz Dosdá, partner and associates of Corporate, together with Zina Safer, head of the legal department of Grupo J. Uriach. Uriach Group. The transaction has also been advised by Iñigo Igartua, Andrea Díez de Uré and Jesús Urriza, partner and associates of Competition, and Rafael Aguilera and Iñigo Arrieta, partner and associates of Banking.
Read full article
Press contact
Director of Business Development, Marketing and Communications
Director of Business Development, Marketing and Communications
More information about
Gómez-Acebo & Pombo
5 days ago 
PUBLICATION
23 Sep, 2026
Paradoxes of non-binding and entire agreement clauses being meta-clauses
Inasmuch as functioning as meta-clauses, non-binding and entire agreement clauses are paradoxical in a number of ways.
23 Sep, 2026 
PUBLICATION
21 Sep, 2026
Pharma & Healthcare No. 50
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
21 Sep, 2026
PUBLICATION
18 Sep, 2026
Resolved bank found liable as pledgee of third-party owned shares in the bank
The fiduciary nature of the managed investment relationship supports the view that the bank should be liable for the loss of the pledged item because there would not have been such loss had the client’s order been executed prior to the bank’s resolution — but not for the reason given in the judgment.
18 Sep, 2026
PUBLICATION
31 Jul, 2026
Automotive and Sustainable Mobility No. 31
Summary of legislative and jurisprudential developments relating to the automotive sector.
31 Jul, 2026
PUBLICATION
17 Jul, 2026
Claim assignment and assignment of right to rescind underlying contract
There is no single answer to the question of whether or not the assignee of a claim has the power to rescind the underlying contract when the assigned debtor defaults. As a general rule, such rescission will not be possible for the assignee.
17 Jul, 2026
PUBLICATION
16 Jul, 2026
New EU regulation on the screening of foreign investments
Regulation (EU) 2026/1386 establishes a harmonised and mandatory framework for the screening of foreign investments in the Union and replaces the previous Regulation (EU) 2019/452. Among its most notable new features are the obligation for all Member States to have a national screening mechanism with harmonised minimum requirements; the inclusion within its scope of investments made by European subsidiaries controlled by third-country investors; the implementation of a two-stage national procedure; and the strengthening of the European cooperation mechanism through a risk-screening system and a more stringent “comply or explain” principle.
Finally, the paper analyses the regulation’s impact on Spain, whose current review mechanism must be adapted in areas such as procedural structure, the review of completed transactions, sectoral expansion, and the penalty regime by 17 January 2028.
16 Jul, 2026
PUBLICATION
08 Jul, 2026
Are company directors directly liable for torts attributable to the company?
Debt from liability in tort for third-party damage or loss arises directly against the directors, without prejudice to the fact that, pursuant to Article 38 CC, it also arises simultaneously against the company, to which the non-contractual acts or omissions of its directors are also attributed. This is so true that the liable company (in debt, for example, with the tax authorities as the person liable for the surcharge and the tax penalty owed) may bring an action for contribution against its directors after settling the debt.
08 Jul, 2026
PUBLICATION
23 Jun, 2026
Pharma & Healthcare No. 49
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
23 Jun, 2026
PUBLICATION
09 Jun, 2026
Partial limitation defences that may be raised in relation to the limitation period within a cartel (Supreme Court Judgment no. 681/2026 of 6 May)
A flawed judgment on a problem that has remained unresolved to date in the truck cartel. The issue is not whether the liability-in-solidum regime applies, but whether co-liable parties can raise personal defences.
09 Jun, 2026